FDA NDC Directory · JSON-LD · Markdown
NDC 85766-263 · VACCINE · INJECTION, SUSPENSION
| Generic name | INFLUENZA A VIRUS A/Tasmania/318/2025 CVR-351 (H1N1) ANTIGEN (MDCK CELL DERIVED, PROPIOLACTONE INACTIVATED), INFLUENZA A VIRUS A/Tasmania/787/2025 CVR-388 (H3N2) ANTIGEN (MDCK CELL DERIVED, PROPIOLACTONE INACTIVATED), INFLUENZA B VIRUS B/Arizona/21/2025 ANTIGEN (MDCK CELL DERIVED, PROPIOLACTONE INAC |
|---|---|
| Labeler / Manufacturer | Sportpharm LLC |
| Marketing category | Biologic License Application · App BLA125408 |
| Dosage form / route | INJECTION, SUSPENSION · INTRAMUSCULAR |
| Active ingredients | INFLUENZA A VIRUS A/TASMANIA/318/2025 CVR-351 (H1N1) ANTIGEN (MDCK CELL DERIVED, PROPIOLACTONE INACTIVATED) (15 ug/.5mL) INFLUENZA A VIRUS A/TASMANIA/787/2025 CVR-388 (H3N2) ANTIGEN (MDCK CELL DERIVED, PROPIOLACTONE INACTIVATED) (15 ug/.5mL) INFLUENZA B VIRUS - B/ARIZONA/21/2025 ANTIGEN (MDCK CELL DERIVED, PROPIOLACTONE INACTIVATED) (15 ug/.5mL) |
| Marketing started | 20260701 |
| Marketing ended | 20270731 |
| Package count | 1 |
Source: openFDA. Public-domain (CC0).